accountbupivacaine pain patch. This study was conducted by DURECT's collaborator, King Pharmaceuticals, which is now owned by Pfizer (NYSE: PFE). In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to DURECT Announces ELADUR�� (TRANSDUR��-Bupivacaine) Phase II Study Results In Chronic Low Back Pain
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account